NRX Pharmaceuticals, Inc. Common Stock (NRXP) is a publicly traded Healthcare sector company. As of July 27, 2026, NRXP trades at $3.63 with a market cap of $160.50M and a P/E ratio of -3.32. NRXP moved -3.47% today. Year to date, NRXP is +33.95%; over the trailing twelve months it is +21.00%. Its 52-week range spans $1.15 to $6.01. Analyst consensus is strong buy with an average price target of $39.67. Rallies surfaces NRXP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
HOPE Therapeutics Treats First Patient with Zeta AI-Guided TMS at Two Clinics: HOPE Therapeutics has begun patient treatments using the FDA-cleared Zeta TMS Navigation System at its Sarasota clinic, following installation at both Sarasota and West Palm Beach sites. The system employs proprietary RealTrack AI to register MRI or CT scans to facial anatomy in under two minutes and track coil positioning with sub-millimetric accuracy.
| Metric | Value |
|---|---|
| Price | $3.63 |
| Market Cap | $160.50M |
| P/E Ratio | -3.32 |
| EPS | $-1.09 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.01 |
| 52-Week Low | $1.15 |
| Volume | 888.11K |
| Avg Volume | 0 |
| Revenue (TTM) | $2.29M |
| Net Income | $-24.54M |
| Gross Margin | 0.00% |
3 analysts cover NRXP: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $39.67.